LDL cholesterol

Generic Cholesterol Meds a Boon for PatientsTwo recent generic cholesterol-lowering drugs are helping reduce health-care costs.
Targeting LDL via PCSK-9 from a Different PathwayA drug underdevelopment may provide another pathway to lowering LDL levels.
Patients who need PCSK9 inhibitors cant get themStudy: PCSK9 inhibitors are being rejected by insurers at very high rates even in high-risk patients like those with familial hypercholesterolemia.
Game-changing cholesterol-buster further reduces heart attack, strokeA new outcomes study shows that the PCSK9 inhibitor Repatha significantly reduced the risk of hard major adverse cardiovascular events in high-risk patients by 20%.
Factoring the metabolic X syndrome
Factoring the metabolic X syndromeAlthough there is debate surrounding the definition of metabolic X syndrome in pediatrics and there are few long-term studies of outcomes in children with metabolic syndrome, pediatric metabolic syndrome needs to be on the radar of all pediatricians interested in ensuring a healthy adult life for their patients.
Study: New cholesterol drugs cost 356 times more than genericsA report from the Alliance of Community Health Plans can help get a better sense of how well drugs help patients compared to other treatment options.
PCSK9 inhibitor benefits patients with statin intolerancePCSK9 inhibitor benefits patients with statin intolerance
FDA approves major cholesterol drugThe FDA on August 27 approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options.
Battle of the cholesterol drugs expectedThis summer, Amgen and Regeneron Pharmaceuticals/ Sanofi will battle it out in the competitive cholesterol market. Repatha and Praluent, respectively, are expected to be approved by the FDA this summer.
Investigational PCSK9 inhibitor lowers LDL-C, may reduce cardiovascular eventsAlirocumab (Praluent), a PCSK9 inhibitor, reduced low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy, according to a study published online in the New England Journal of Medicine.